Access broad B cell diversity to select better antibody lead candidates in just days.
Increase your chances of finding rare functional antibody therapeutic candidates by screening the plasma B cell repertoire using the Berkeley Lights Platform.
Plasma B discovery using the Beacon® optofluidic system bypasses time-consuming and inefficient hybridoma fusion.
Plasma B cells are screened using binding and functional assays to select only the most qualified antibody lead candidates. OptoSeq™BCR enables automated recovery of broad antibody sequence diversity in under a week.
With a NanoPen™chamber volume of only 250 pico liters, reactions are fast and precise. Complete assays in less than 1 hour, then reset your chips to enable the next assay to begin. Better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.
B cells can be screened from multiple organs (spleen, bone marrow, lymph nodes) and cultured for multiple days in specialized media to enable multiple screens from a single cell sample.
Learn how antibody discovery is changing in today’s therapeutic space. Case studies presented by Abveris highlight accelerated development of next-generation antibody therapeutics.
This 4-page brochure explains how the Beacon platform removes tedious steps from the Antibody Discovery workflow and automates phenotype and genotype screening.
Discover how you can maximize hit recovery and rapidly down-select blocking antibodies from plasma B cells in a single day.